1-13 of 13
Miloslav Beran
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acquisition of RAS mutations contributes to progression of CMML from the dysplastic to the proliferative variant

Clara Ricci, Francesco Onida, Elisa Fermo, Claudia Miranda, Davide Soligo, Miloslav Beran, Giorgio Lambertenghi Deliliers
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 152.
Published: 01 May 2007
View article titled, Acquisition of RAS mutations contributes to progression of CMML from the dysplastic to the proliferative variant
Journal Articles

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in adult patients (pts) with imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

Francis J. Giles, Oliver Ottmann, Jorge Cortes, Barbara Wassman, Lydia Wunderle, Susan O’Brien, Dan Jones, Andreas Hochhaus, Srdan Verstovsek, Patricia Rae, Kristine Rose, Leila Alland, Margaret Dugan, Paul Manley, Miloslav Beran, Maher Albitar, Hagop Kantarjian
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 935.
Published: 01 May 2005
View article titled, AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in adult patients (pts) with imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)
Journal Articles

Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line

Clara Ricci, Barbara Scappini, Vladimir Divoky, Simona Gatto, Francesco Onida, Srdan Verstovsek, Hagop M. Kantarjian, Miloslav Beran
Journal: Cancer Research
Cancer Res (2002) 62 (21): 5995–5998.
Published: 01 November 2002
View article titled, Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line
Open the PDF for Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line in another window
Journal Articles

Antisense RNA Inhibition of Phosphoprotein p18 Expression Abrogates the Transformed Phenotype of Leukemic Cells

Sima Jeha, Xiang-Nong Luo, Miloslav Beran, Hagop Kantarjian, George F. Atweh
Journal: Cancer Research
Cancer Res (1996) 56 (6): 1445–1450.
Published: 01 March 1996
View article titled, Antisense RNA Inhibition of Phosphoprotein p18 Expression Abrogates the Transformed Phenotype of Leukemic Cells
Open the PDF for Antisense RNA Inhibition of Phosphoprotein p18 Expression Abrogates the Transformed Phenotype of Leukemic Cells in another window
Journal Articles

Biological Properties and Growth in SCID Mice of a New Myelogenous Leukemia Cell Line (KBM-5) Derived from Chronic Myelogenous Leukemia Cells in the Blastic Phase

Miloslav Beran, Pavel Pisa, Susan O'Brien, Razelle Kurzrock, Michael Siciliano, Ann Cork, Borje S. Andersson, Vipin Kohli, Hagop Kantarjian
Journal: Cancer Research
Cancer Res (1993) 53 (15): 3603–3610.
Published: 01 August 1993
View article titled, Biological Properties and Growth in <em>SCID</em> Mice of a New Myelogenous Leukemia Cell Line (KBM-5) Derived from Chronic Myelogenous Leukemia Cells in the Blastic Phase
Open the PDF for Biological Properties and Growth in <em>SCID</em> Mice of a New Myelogenous Leukemia Cell Line (KBM-5) Derived from Chronic Myelogenous Leukemia Cells in the Blastic Phase in another window
Journal Articles

Clinical Implications of Decreased Retinoblastoma Protein Expression in Acute Myelogenous Leukemia

Steven M. Kornblau, Hong-Ji Xu, Auro del Giglio, Shi-Xue Hu, Wei Zhang, Leslie Calvert, Miloslav Beran, Elihu Estey, Michael Andreeff, Jose Trujillo, Marjorie A. Cork, Terry L. Smith, William F. Benedict, Albert B. Deisseroth
Journal: Cancer Research
Cancer Res (1992) 52 (17): 4587–4590.
Published: 01 September 1992
View article titled, Clinical Implications of Decreased Retinoblastoma Protein Expression in Acute Myelogenous Leukemia
Open the PDF for Clinical Implications of Decreased Retinoblastoma Protein Expression in Acute Myelogenous Leukemia in another window
Journal Articles

CI-973, a New Platinum Derivative with Potential Antileukemic Activity

Susan O'Brien, Hagop Kantarjian, Emil Freireich, Dennis Johnston, Kim Nguyen, Miloslav Beran
Journal: Cancer Research
Cancer Res (1992) 52 (15): 4130–4134.
Published: 01 August 1992
View article titled, CI-973, a New Platinum Derivative with Potential Antileukemic Activity
Open the PDF for CI-973, a New Platinum Derivative with Potential Antileukemic Activity in another window
Journal Articles

Phase I Clinical Investigation of Benzisoquinolinedione (Amonafide) in Adults with Refractory or Relapsed Acute Leukemia

Susan O'Brien, John A. Benvenuto, Elihu Estey, Miloslav Beran, Tyrone B. Felder, Michael Keating
Journal: Cancer Research
Cancer Res (1991) 51 (3): 935–938.
Published: 01 February 1991
View article titled, Phase I Clinical Investigation of Benzisoquinolinedione (Amonafide) in Adults with Refractory or Relapsed Acute Leukemia
Open the PDF for Phase I Clinical Investigation of Benzisoquinolinedione (Amonafide) in Adults with Refractory or Relapsed Acute Leukemia in another window
Journal Articles

The Effects of Acetaldophosphamide, a Novel Stable Aldophosphamide Analogue, on Normal Human and Leukemic Progenitor Cells in Vitro: Implications for Use in Bone Marrow Purging

Miloslav Beran, Borje S. Andersson, Yuqiang Wang, Kenneth B. McCredie, David Farquhar
Journal: Cancer Research
Cancer Res (1988) 48 (2): 339–345.
Published: 01 January 1988
View article titled, The Effects of Acetaldophosphamide, a Novel Stable Aldophosphamide Analogue, on Normal Human and Leukemic Progenitor Cells <em>in Vitro</em>: Implications for Use in Bone Marrow Purging
Open the PDF for The Effects of Acetaldophosphamide, a Novel Stable Aldophosphamide Analogue, on Normal Human and Leukemic Progenitor Cells <em>in Vitro</em>: Implications for Use in Bone Marrow Purging in another window
Journal Articles

Development and Characterization of a Human Myelogenous Leukemia Cell Line Resistant to 4′-(9-Acridinylamino)-3-methanesulfon-m-anisidide

Miloslav Beran, Borje S. Andersson
Journal: Cancer Research
Cancer Res (1987) 47 (7): 1897–1904.
Published: 01 April 1987
View article titled, Development and Characterization of a Human Myelogenous Leukemia Cell Line Resistant to 4′-(9-Acridinylamino)-3-methanesulfon-<em>m</em>-anisidide
Open the PDF for Development and Characterization of a Human Myelogenous Leukemia Cell Line Resistant to 4′-(9-Acridinylamino)-3-methanesulfon-<em>m</em>-anisidide in another window
Journal Articles

In Vitro Toxicity and DNA Cleaving Capacity of Benzisoquinolinedione (Nafidimide; NSC 308847) in Human Leukemia

Borje S. Andersson, Miloslav Beran, Milorad Bakic, Lynn E. Silberman, Robert A. Newman, Leonard A. Zwelling
Journal: Cancer Research
Cancer Res (1987) 47 (4): 1040–1044.
Published: 01 February 1987
View article titled, <em>In Vitro</em> Toxicity and DNA Cleaving Capacity of Benzisoquinolinedione (Nafidimide; NSC 308847) in Human Leukemia
Open the PDF for <em>In Vitro</em> Toxicity and DNA Cleaving Capacity of Benzisoquinolinedione (Nafidimide; NSC 308847) in Human Leukemia in another window
Journal Articles

Drug Sensitivity and Cross-Resistance of the 4′-(9-Acridinylamino)methanesulfon-m-anisidide-resistant Subline of HL-60 Human Leukemia

Marcel Odaimi, Borje S. Andersson, Kenneth B. McCredie, Miloslav Beran
Journal: Cancer Research
Cancer Res (1986) 46 (7): 3330–3333.
Published: 01 July 1986
View article titled, Drug Sensitivity and Cross-Resistance of the 4′-(9-Acridinylamino)methanesulfon-<em>m</em>-anisidide-resistant Subline of HL-60 Human Leukemia
Open the PDF for Drug Sensitivity and Cross-Resistance of the 4′-(9-Acridinylamino)methanesulfon-<em>m</em>-anisidide-resistant Subline of HL-60 Human Leukemia in another window
Journal Articles

Significance of Cellular Pharmacokinetics for the Cytotoxic Effects of Daunorubicin

Börje Andersson, Miloslav Beran, Curt Peterson, Bernhard Tribukait
Journal: Cancer Research
Cancer Res (1982) 42 (1): 178–183.
Published: 01 January 1982
View article titled, Significance of Cellular Pharmacokinetics for the Cytotoxic Effects of Daunorubicin
Open the PDF for Significance of Cellular Pharmacokinetics for the Cytotoxic Effects of Daunorubicin in another window